Kidney Cancer Trial, Recruiting NCT07646847 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT07646847
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with kidney, bladder, breast, or lung cancer, confirmed by a doctor
  • You are within about two weeks of starting a specific type of immunotherapy treatment (called a PD-1 or PD-L1 checkpoint inhibitor), either on its own or alongside other treatments
  • You are 18 years old or older
  • You are not currently pregnant and are not breastfeeding
  • You have at least one basic everyday need that is unmet, such as access to food, transportation, or stable housing (this is checked using a short screening tool)
  • You live in the New York metro area, including Long Island, New Jersey, Connecticut, or Pennsylvania
  • You are able to speak English or Spanish
  • You do not have severe psychiatric symptoms that would prevent you from completing surveys, interviews, or giving informed consent (confirm with trial site)
  • You do not have a condition affecting memory or thinking, such as delirium or dementia, that would prevent you from giving informed consent or taking part in data collection (confirm with trial site)

Who may not be able to join:

  • People who have not been diagnosed with kidney, bladder, breast, or lung cancer
  • People who are pregnant or currently nursing
  • People who are not starting the specific immunotherapy treatment within the required time window
  • People who do not live in the specified areas near New York
  • People who are unable to speak English or Spanish
  • People with serious active psychiatric symptoms that would prevent meaningful participation (confirm with trial site)
  • People with significant memory or thinking impairments, such as dementia or delirium (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Francesca Gany, MD, MS, Memorial Sloan Kettering Cancer Center

Phone: 646-888-8054

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
9 June 2026
Est. completion
9 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Immune Checkpoint Inhibitors/ICI continuation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov